123 related articles for article (PubMed ID: 9368338)
1. Bone marrow transplantation for therapy in autoimmune disease.
Exner BG; Groninger JH; Ildstad ST
Stem Cells; 1997; 15 Suppl 1():171-5; discussion 175-6. PubMed ID: 9368338
[TBL] [Abstract][Full Text] [Related]
2. Chimerism and tolerance: from freemartin cattle and neonatal mice to humans.
Jankowski RA; Ildstad ST
Hum Immunol; 1997 Feb; 52(2):155-61. PubMed ID: 9077564
[TBL] [Abstract][Full Text] [Related]
3. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
4. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
5. A partial conditioning strategy for achieving mixed chimerism in the rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment.
Gammie JS; Li S; Colson YL; Demetris AJ; Neipp M; Ildstad ST; Pham SM
Exp Hematol; 1998 Sep; 26(10):927-35. PubMed ID: 9728927
[TBL] [Abstract][Full Text] [Related]
6. Stem cell transplantation for autoimmune diseases: what can we learn from experimental models?
Ikehara S
Autoimmunity; 2008 Dec; 41(8):563-9. PubMed ID: 18958757
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats.
Jäger MD; Liu JY; Timrott KF; Popp FC; Stoeltzing O; Lang SA; Piso P; Geissler EK; Schlitt HJ; Dahlke MH
Exp Hematol; 2007 Jan; 35(1):164-70. PubMed ID: 17198885
[TBL] [Abstract][Full Text] [Related]
8. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
[TBL] [Abstract][Full Text] [Related]
9. Stem cell transplantation for severe autoimmune diseases: progress and problems.
Marmont AM
Haematologica; 1998 Aug; 83(8):733-43. PubMed ID: 9793258
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients.
Westerhof GR; Ploemacher RE; Boudewijn A; Blokland I; Dillingh JH; McGown AT; Hadfield JA; Dawson MJ; Down JD
Cancer Res; 2000 Oct; 60(19):5470-8. PubMed ID: 11034090
[TBL] [Abstract][Full Text] [Related]
11. Impact of bone marrow transplantation on type I diabetes.
Domenick MA; Ildstad ST
World J Surg; 2001 Apr; 25(4):474-80. PubMed ID: 11344401
[TBL] [Abstract][Full Text] [Related]
12. A new bone marrow transplantation method for stem cell disorders.
Ikehara S
Ann N Y Acad Sci; 2009 Sep; 1173():774-80. PubMed ID: 19758228
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
14. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
15. Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation.
Elkin G; Prigozhina TB; Slavin S
Exp Hematol; 2004 Jun; 32(6):579-84. PubMed ID: 15183899
[TBL] [Abstract][Full Text] [Related]
16. Long-term observation after simultaneous lung and intra-bone marrow-bone marrow transplantation.
Kaneda H; Adachi Y; Saito Y; Ikebukuro K; Machida H; Suzuki Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Wang J; Imamura H; Ikehara S
J Heart Lung Transplant; 2005 Sep; 24(9):1415-23. PubMed ID: 16143265
[TBL] [Abstract][Full Text] [Related]
17. Intra-bone marrow-bone marrow transplantation: a new strategy for treatment of stem cell disorders.
Ikehara S
Ann N Y Acad Sci; 2005 Jun; 1051():626-34. PubMed ID: 16127003
[TBL] [Abstract][Full Text] [Related]
18. A novel method of bone marrow transplantation (BMT) for intractable autoimmune diseases.
Ikehara S
J Autoimmun; 2008 May; 30(3):108-15. PubMed ID: 18249091
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT).
Vindeløv L
Eur J Haematol; 2001 Feb; 66(2):73-82. PubMed ID: 11168513
[TBL] [Abstract][Full Text] [Related]
20. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
